No Data
No Data
Aerovate Therapeutics Board Member Maha Katabi Resigns
12 Health Care Stocks Moving In Tuesday's After-Market Session
Oppenheimer Downgrades Aerovate(AVTE.US) to Hold Rating, Cuts Target Price to $3
Oppenheimer analyst Andreas Argyrides downgrades $Aerovate(AVTE.US)$ to a hold rating, and adjusts the target price from $41 to $3.According to TipRanks data, the analyst has a success rate of 44.7%
Analysts Conflicted on These Healthcare Names: Oric Pharmaceuticals (ORIC), Aerovate Therapeutics (AVTE) and McKesson (MCK)
Aerovate | 10-Q: Q2 2024 Earnings Report
Aerovate Therapeutics Shares Are Trading Higher After the Company Announced It Is Exploring Strategic Alternatives.